Bruce Cree, MD of the University of California San Francisco discusses current treatment options for neuromyelitis optica spectrum disorder (NMOSD).
NMOSD is a rare central nervous disorder that primarily affects the spinal cord and optic nerves. Symptoms of NMOSD may include blindness in one or both eyes, weakness or paralysis of arms or legs, spasming, loss of sensation, uncontrollable vomiting and hiccups, and bladder/bowel problems due to spinal cord damage.
As Dr. Cree explains, there are currently two treatment options for NMOSD patients. Eculizumab, a drug that had been approved for the treatment of other disorders such as atypical hemolytic uremic syndrome was approved for the treatment of NMOSD almost two years ago. However, this treatment requires NMOSD patients to undergo bi-weekly infusions. The second approved treatment, inebilizumab is administered bi-annually, making treatment of NMOSD more convenient for patients, according to Dr. Cree.
For more information on NMOSD and other rare neurological disorders, visit checkrare.com/diseases/autoimmune-auto-inflammatory-disorders/